Digital Twins Emerge for Bioprocess Optimization
Digital twins are gaining traction in biomanufacturing for process optimization and real-time troubleshooting. Recent work at Berkeley Lab underscores their use in predictive “what-if” scenario testing, while other applications focus on diagnosing failure mechanisms in unit operations like tangential flow filtration (TFF). These virtual models allow teams to refine production strategies and predict deviations before real-world implementation.
- Digital twin integration relies on connecting disparate data systems, including Manufacturing Execution Systems (MES), Laboratory Information Management Systems (LIMS), and Enterprise Resource Planning (ERP) to create a unified and traceable view of the manufacturing process. This holistic data approach is a core component of the Pharma 4.0 framework, which aims to increase connectivity and data integrity in regulated pharmaceutical environments. - In viral vector manufacturing, a primary challenge is the variability and complexity of the production process, which, unlike monoclonal antibody production, is not standardized across the industry. Digital twins can help address this by modeling and predicting the impact of process parameter changes on vector quality attributes, such as the ratio of full to empty capsids. - Leading Contract Development and Manufacturing Organizations (CDMOs) are developing "plug and play" viral vector manufacturing platforms, such as AGC Biologics' BravoAAV™ and ProntoLVV™, to streamline the transition to GMP manufacturing. These platforms offer standardized cell lines, plasmids, and analytical methods to accelerate timelines, with some aiming for GMP readiness in as little as 9-12 months from receiving the plasmid. - The viral vector CDMO market is projected to grow from approximately $1.02 billion in 2025 to $2.44 billion by 2030, reflecting a compound annual growth rate (CAGR) of 19%. This growth is fueled by an expanding pipeline of cell and gene therapies and the need for scalable, regulatory-compliant manufacturing solutions. - A significant barrier to broader digital adoption in cell and gene therapy manufacturing is data fragmentation, where process, quality, and clinical data reside in separate systems. Industry groups are working to establish common data standards to enable the large-scale data sharing needed to train more effective predictive models and AI tools. - The biotech funding climate in 2025 showed a "K-shaped" recovery, with well-funded, clinically validated programs moving forward while early-stage companies faced tougher financing conditions. Global biotech funding surpassed $200 billion in 2025, a 15% increase over 2024, with significant investment directed toward gene and cell therapies and AI-driven drug discovery platforms. - Real-world applications of digital twins in biomanufacturing have already demonstrated value; for instance, GlaxoSmithKline utilized a digital twin to reduce production variability and enhance yield consistency in their vaccine manufacturing process by simulating and fine-tuning parameters like cell density and nutrient levels. - The implementation of digital technologies often starts with smaller, targeted projects focused on monitoring before advancing to process control. This incremental approach helps manage the complexities of revalidation in GMP environments and builds confidence in the technology's return on investment.
